Name: Allan David Struthers

POST CURRENTLY HELD: Professor of Cardiovascular Medicine & Therapeutics,Honorary Consultant Physician and Head of The Division of Medicine And Therapeutics

Allan Struthers  

Degrees & Diplomas:
1973
Bsc (Hons) Biochemistry, Glasgow
1977
MBChB (Hons) Glasgow
1979
DCH
1980
MRCP (UK)
1984
MD
1990
FRCP( Glas) FRCP( Ed )
1992
FRCP
1994
FESC
   
 
   


Main Clinical Interests:

Chronic Heart Failure (Guidelines for the diagnosis and treatment of chronic heart failure)

Main Research Interests:

Aldosterone: We were the first to describe that aldosterone blockade increases vascular nitric oxide bioactivity and decreases myocardial collagen markers in the blood. Such effects probably explain why aldosterone blockade reduces mortality in chronic heart failure.

Xanthine Oxidase ( XO): We have explored the potential for XO inhibition and found that it also improves endothelial dysfunction, both in heart failure and diabetes. We recently showed that XO inhibition also reduces plasma BNP in chronic heart failure.

Left Ventricular Hypertrophy: Left ventricular hypertrophy (LVH) is a risk predictor which is sadly ignored in clinical practice. We are promoting the idea that identifying and treating LVH in high risk normotensive patients ( eg diabetes or post CVA patients) could deliver huge benefits in terms of reducing cardiac deaths.

Endothelial Dysfunction : Endothelial dysfunction is increasingly recognised as a reliable surrogate to test whether novel therapies are likely to reduce futurecardiovascular events. We are able to test out the effect of many novel therapies by assessing whether or not they improve endothelial dysfunction.

 
 

 

Most Recent Publications
Kalra P, Clague JR, Bulger AP, Anker SD, Poole Wilson PA, Struthers AD, Coats A. Myocardial production of CNP in congestive heart failure. Circulation 2003, 107: 571-573.
Wong KYK, MacWalter R, Fraser HW, Crombie I, Ogston SA, Struthers AD. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002, 23: 788-793.
Farquharson C, Butler R, Hill A, Belch J, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
Struthers AD, Morris AD. Screening for and treating LV abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002; 359: 1430-1432.
Farquharson C, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol (2002) 39, 767-775.
Kelly R et al.. Prevalence of treatable LV systolic dysfunction in patients who present with noncardiac vascular episodes. J Am Coll Cardiol 2002, 39, 219-224.
Farquharson C, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol (2002) 39, 767-775.
Kelly R et al.. Prevalence of treatable LV systolic dysfunction in patients who present with noncardiac vascular episodes. J Am Coll Cardiol 2002, 39, 219-224.
Yee KM, Pringle SD, Struthers AD, Circadian influence of aldosterone blockade on QT dispersion and Heart Rate Variability in CHF. J Am Coll Cardiol (2001) 37, 1800-1807.
Farquharson C, Struthers AD. Spironolactone increases NO bioactivity, improves endothelial vasodilator dysfunction, and suppresses AI/AII conversion in chronic heart failure. Circulation (2000): 101: 594-597.
Struthers AD et al. Nonadherence with ACE inhibitor therapy: a comparison of different ways of measuring it. J Am Coll Cardiol 1999: 34: 2072-7.
Butler RA, Morris A, Belch JJF, Hill A, Struthers AD. Allopurinol normalises endothelial dysfunction in type 2 diabetes with mild hypertension. Hypertension 2000, 35, 746-751.

 

Address
Secretary
   

 

A to Z Index | Search the University

Maintained by: a.z.hill@dundee.ac.uk.

Disclaimer | Privacy

Page last updated: Thursday 25 March 2010 02:43 PM